These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23121190)

  • 21. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
    Fabbiani M; Bracciale L; Doino M; D'Avino A; Marzocchetti A; Navarra P; Cauda R; De Luca A; Di Giambenedetto S
    J Infect; 2011 Apr; 62(4):319-21. PubMed ID: 21329725
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy of atazanavir in simplification regimens].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
    Squires KE; Johnson M; Yang R; Uy J; Sheppard L; Absalon J; McGrath D
    J Antimicrob Chemother; 2011 Feb; 66(2):363-70. PubMed ID: 21148235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complicated atazanavir-associated cholelithiasis: a report of 14 cases.
    Rakotondravelo S; Poinsignon Y; Borsa-Lebas F; de la Blanchardière A; Michau C; Jantzem H; Massy N; Polard E; Giroux F; Kerspern H; Meskar A; Hue G; Tribut O; Arvieux C; Tattevin P
    Clin Infect Dis; 2012 Nov; 55(9):1270-2. PubMed ID: 22820540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
    Squires K; Lazzarin A; Gatell JM; Powderly WG; Pokrovskiy V; Delfraissy JF; Jemsek J; Rivero A; Rozenbaum W; Schrader S; Sension M; Vibhagool A; Thiry A; Giordano M
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1011-9. PubMed ID: 15247553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy.
    Johnston SS; Juday T; Esker S; Espindle D; Chu BC; Hebden T; Uy J
    Value Health; 2013; 16(2):418-25. PubMed ID: 23538194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
    Vallecillo-Sánchez G; Guelar-Grimberg A; González-Mena A; Knobel-Freud H
    Enferm Infecc Microbiol Clin; 2008 May; 26(5):316-7. PubMed ID: 18479652
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
    Wood R; Phanuphak P; Cahn P; Pokrovskiy V; Rozenbaum W; Pantaleo G; Sension M; Murphy R; Mancini M; Kelleher T; Giordano M
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):684-92. PubMed ID: 15167287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.
    Subashini D; Dinesha TR; Boobalan J; Samuel LC; Poongulali S; Pradeep A; Solomon SS; Solomon S; Balakrishnan P; Saravanan S
    Indian J Pharmacol; 2016; 48(5):582-585. PubMed ID: 27721547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
    Ribaudo HJ; Daar ES; Tierney C; Morse GD; Mollan K; Sax PE; Fischl MA; Collier AC; Haas DW;
    J Infect Dis; 2013 Feb; 207(3):420-5. PubMed ID: 23148286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.
    Jansen K; Sönnerborg A; Brockmeyer N; Thalme A; Svedhem V; Dupke S; Eychenne JL; Nakonz T; Jimenez-Exposito MJ; Pugliese P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):564-73. PubMed ID: 23016535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.
    Esker S; Albano J; Uy J; Arikan D; Jimenez-Exposito MJ; Seekins D; Tilson H
    AIDS Patient Care STDS; 2012 Jun; 26(6):307-11. PubMed ID: 22404239
    [No Abstract]   [Full Text] [Related]  

  • 37. A case of transient hyperphosphatasemia of infancy and early childhood in an HIV-positive adult possibly related to atazanavir.
    Trower K; Wilmot R; Barlow G; Thaker H
    AIDS; 2006 Jan; 20(1):135-6. PubMed ID: 16327337
    [No Abstract]   [Full Text] [Related]  

  • 38. Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals.
    Pastori D; Esposito A; Cagliuso M; Conti V; Mezzaroma I
    AIDS; 2009 Oct; 23(16):2233-4. PubMed ID: 19823121
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
    Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
    López-Cortés LF
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.